Novo Nordisk lifts guidance as Wegovy pill sales beat forecasts
Novo Nordisk lifts guidance as Wegovy pill sales beat forecasts
Novo Nordisk lifts guidance as Wegovy pill sales beat forecasts
Key points
اہم نکات
मुख्य बातें
- Danish drugmaker Novo Nordisk has raised its full-year guidance after strong sales of its Wegovy weight-loss pill, which is now sold in eight markets after launching in the United States in January.
- Third-quarter sales of the pill reached 5.39 billion Danish kroner, about 810 million dollars, beating market expectations, while adjusted group sales rose 6 percent to 79.2 billion kroner.
- The company now expects adjusted sales and operating profit to range from a 2 percent decline to 2 percent growth this year, better than its earlier forecast of a decline of up to 6 percent.
- Danish drugmaker Novo Nordisk has raised its full-year guidance after strong sales of its Wegovy weight-loss pill, which is now sold in eight markets after launching in the United States in January.
- Third-quarter sales of the pill reached 5.39 billion Danish kroner, about 810 million dollars, beating market expectations, while adjusted group sales rose 6 percent to 79.2 billion kroner.
- The company now expects adjusted sales and operating profit to range from a 2 percent decline to 2 percent growth this year, better than its earlier forecast of a decline of up to 6 percent.
- Danish drugmaker Novo Nordisk has raised its full-year guidance after strong sales of its Wegovy weight-loss pill, which is now sold in eight markets after launching in the United States in January.
- Third-quarter sales of the pill reached 5.39 billion Danish kroner, about 810 million dollars, beating market expectations, while adjusted group sales rose 6 percent to 79.2 billion kroner.
- The company now expects adjusted sales and operating profit to range from a 2 percent decline to 2 percent growth this year, better than its earlier forecast of a decline of up to 6 percent.
Danish drugmaker Novo Nordisk has raised its full-year guidance after strong sales of its Wegovy weight-loss pill, which is now sold in eight markets after launching in the United States in January. Third-quarter sales of the pill reached 5.39 billion Danish kroner, about 810 million dollars, beating market expectations, while adjusted group sales rose 6 percent to 79.2 billion kroner. The company now expects adjusted sales and operating profit to range from a 2 percent decline to 2 percent growth this year, better than its earlier forecast of a decline of up to 6 percent. It also said its finance chief will leave at the end of the year.
Danish drugmaker Novo Nordisk has raised its full-year guidance after strong sales of its Wegovy weight-loss pill, which is now sold in eight markets after launching in the United States in January. Third-quarter sales of the pill reached 5.39 billion Danish kroner, about 810 million dollars, beating market expectations, while adjusted group sales rose 6 percent to 79.2 billion kroner. The company now expects adjusted sales and operating profit to range from a 2 percent decline to 2 percent growth this year, better than its earlier forecast of a decline of up to 6 percent. It also said its finance chief will leave at the end of the year.
Danish drugmaker Novo Nordisk has raised its full-year guidance after strong sales of its Wegovy weight-loss pill, which is now sold in eight markets after launching in the United States in January. Third-quarter sales of the pill reached 5.39 billion Danish kroner, about 810 million dollars, beating market expectations, while adjusted group sales rose 6 percent to 79.2 billion kroner. The company now expects adjusted sales and operating profit to range from a 2 percent decline to 2 percent growth this year, better than its earlier forecast of a decline of up to 6 percent. It also said its finance chief will leave at the end of the year.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।